Icatibanto Glenmark (Icatibant)

Icatibant blocks the bradykinin B2 receptor, preventing bradykinin from causing blood‑vessel dilation and increased permeability. By inhibiting this pathway, the drug stops the cascade that leads to the swelling characteristic of hereditary angioedema.

The dose of icatibant is determined by the prescribing healthcare professional. In clinical practice, a single subcutaneous injection is often administered, and a second dose may be given if symptoms persist, but the exact regimen is set by the prescriber based on the patient’s condition.

Safety data for icatibant during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The primary alternative for hereditary angioedema is C1‑inhibitor concentrate, which replaces the missing protein. Icatibant, by contrast, blocks the downstream bradykinin receptor. Both are effective, but icatibant offers a rapid subcutaneous route, whereas C1‑inhibitor is given intravenously and works by restoring the natural inhibitor.

The product must be stored at 2‑8 °C in a refrigerator. Keep it in the original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

Icatibanto Glenmark is administered as a subcutaneous injection, typically into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the medication is injected using a sterile needle according to the prescriber’s instructions.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, unexpected angioedema unrelated to hereditary disease, and significant hypotension. Patients should be monitored closely after injection, and any signs of severe reaction require immediate medical attention.

Icatibant should not be used in individuals with a known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients receiving ACE inhibitors or other agents that increase bradykinin levels, as the combination may raise the risk of angioedema.